{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:56:27Z","timestamp":1761746187025,"version":"3.40.5"},"reference-count":25,"publisher":"Pharmaceutical Society of Japan","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,5,8]]},"DOI":"10.1248\/bpb.b24-00834","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T22:07:12Z","timestamp":1746655632000},"page":"537-544","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of De-Escalation to Cefmetazole in Patients with Bacteremic Urinary Tract Infections Caused by Extended-Spectrum &lt;i&gt;\u03b2&lt;\/i&gt;-Lactamase-Producing &lt;i&gt;Escherichia coli&lt;\/i&gt;"],"prefix":"10.1248","volume":"48","author":[{"given":"Takaya","family":"Namiki","sequence":"first","affiliation":[{"name":"Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"},{"name":"Department of Pharmacy, Tokyo Bay Urayasu Ichikawa Medical Center, 3\u20134\u201332 Todaijima, Urayasu, Chiba 279\u20130001, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"},{"name":"Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motonori","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo 160\u20138582, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Infection Control, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo 160\u20138582, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Seyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432\u20131 Horinouchi, Hachioji, Tokyo 192\u20130392, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Iketani","sequence":"additional","affiliation":[{"name":"Division of Academic Research Support, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo 160\u20138582, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Uwamino","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160\u20138582, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Jibiki","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kawazoe","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"},{"name":"Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisakazu","family":"Ohtani","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo 160\u20138582, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160\u20138582, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rentaro","family":"Oda","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Tama General Medical Center Tokyo Metropolitan Hospital Organization, 2\u20138\u201329 Musashidai, Fuchu, Tokyo 183\u20138524, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Hashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokyo Bay Urayasu Ichikawa Medical Center, 3\u20134\u201332 Todaijima, Urayasu, Chiba 279\u20130001, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayo","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"},{"name":"Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"},{"name":"Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"doi-asserted-by":"crossref","unstructured":"1) Septimus EJ. Antimicrobial resistance: an antimicrobial\/diagnostic stewardship and infection prevention approach. <i>Med. Clin. North Am.<\/i>, <b>102<\/b>, 819\u2013829 (2018).","key":"1","DOI":"10.1016\/j.mcna.2018.04.005"},{"doi-asserted-by":"crossref","unstructured":"2) Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. <i>Spectrum \u03b2-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa) Version 1.1 2<\/i>. Running Title: AMR Treatment Guidance. IDSA, Arlington Virginia United States (2022).","key":"2","DOI":"10.1093\/cid\/ciac268"},{"unstructured":"3) CDC, Atlanta, Georgia, \u201cAntibiotic resistance threats in the United States.\u201d: &lt;https:\/\/www.cdc.gov\/antimicrobial-resistance\/media\/pdfs\/2019-ar-threats-report-508.pdf&gt;, accessed 20 December, 2023.","key":"3"},{"doi-asserted-by":"crossref","unstructured":"4) Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among <i>Klebsiella pneumoniae<\/i> isolates risk factors, molecular characteristics, and susceptibility patterns. <i>Infect. Control Hosp. Epidemiol.<\/i>, <b>30<\/b>, 666\u2013671 (2009).","key":"4","DOI":"10.1086\/598244"},{"doi-asserted-by":"crossref","unstructured":"5) Paiboonvong T, Tedtaisong P, Montakantikul P, Gorsanan S, Tantisiriwat W. Correlation between carbapenem consumption and carbapenems susceptibility profiles of <i>Acinetobacter baumannii<\/i> and <i>Pseudomonas aeruginosa<\/i> in an academic medical center in Thailand. <i>Antibiotics (Basel)<\/i>, <b>11<\/b>, 143 (2022).","key":"5","DOI":"10.3390\/antibiotics11020143"},{"unstructured":"6) Exner M, Bhattacharya S, Christiansen B, Gebel J, Goroncy-Bermes P, Hartemann P, Heeg P, Ilschner C, Kramer A, Larson E, Merkens W, Mielke M, Oltmanns P, Ross B, Rotter M, Schmithausen RM, Sonntag HG, Trautmann M. Antibiotic resistance: what is so special about multidrug-resistant Gram-negative bacteria? <i>GMS Hyg. Infect. Control.<\/i>, <b>12<\/b>, Doc05  (2017).","key":"6"},{"doi-asserted-by":"crossref","unstructured":"7) Armstrong T, Fenn SJ, Hardie KR. JMM Profile: carbapenems: a broad-spectrum antibiotic. <i>J. Med. Microbiol.<\/i>, <b>70<\/b>, 001462 (2021).","key":"7","DOI":"10.1099\/jmm.0.001462"},{"doi-asserted-by":"crossref","unstructured":"8) Pitout JDD, Laupland KB. Extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: an emerging public-health concern. <i>Lancet Infect. Dis.<\/i>, <b>8<\/b>, 159\u2013166 (2008).","key":"8","DOI":"10.1016\/S1473-3099(08)70041-0"},{"doi-asserted-by":"crossref","unstructured":"9) Matsumura Y, Yamamoto M, Nagao M, Komori T, Fujita N, Hayashi A, Shimizu T, Watanabe H, Doi S, Tanaka M, Takakura S, Ichiyama. Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-<i>\u03b2<\/i>-lactamase-producing <i>Escherichia coli<\/i> bacteremia. <i>Antimicrob. Agents Chemother<\/i>, <b>59<\/b>, 5107\u20135113 (2015).","key":"9","DOI":"10.1128\/AAC.00701-15"},{"doi-asserted-by":"crossref","unstructured":"10) Fukuchi T, Iwata K, Kobayashi S, Nakamura T, Ohji G. Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems. <i>BMC Infect. Dis.<\/i>, <b>16<\/b>, 427 (2016).","key":"10","DOI":"10.1186\/s12879-016-1770-1"},{"doi-asserted-by":"crossref","unstructured":"11) Hayakawa K, Matsumura Y, Uemura K, Tsuzuki S, Sakurai A, Tanizaki R, Shinohara K, Hashimoto T, Hase R, Matono T, Kato H, Mawatari M, Hara H, Hamada Y, Saito S, Ohmagari N, Doi  Y. Effectiveness of cefmetazole <i>versus<\/i> meropenem for invasive urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing <i>Escherichia coli. Antimicrob<\/i>. <i>Agents Chemother.<\/i>, <b>67<\/b>, e0051023 (2023).","key":"11","DOI":"10.1128\/aac.00510-23"},{"doi-asserted-by":"crossref","unstructured":"12) Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. <i>Clin. Infect. Dis.<\/i>, <b>ciae403<\/b> (2024).","key":"12","DOI":"10.1093\/cid\/ciae403"},{"doi-asserted-by":"crossref","unstructured":"13) Lamas Ferreiro JL, \u00c1lvarez Otero J, Gonz\u00e1lez Gonz\u00e1lez L, Novoa Lamazares L, Arca Blanco A, Berm\u00fadez Sanjurjo JR, Rodr\u00edguez Conde I, Fern\u00e1ndez Soneira M, de la Fuente Aguado J. Pseudomonas aeruginosa urinary tract infections in hospitalized patients: mortality and prognostic factors. <i>PLOS ONE<\/i>, <b>12<\/b>, e0178178 (2017).","key":"13","DOI":"10.1371\/journal.pone.0178178"},{"doi-asserted-by":"crossref","unstructured":"14) Tabibian JH, Gornbein J, Heidari A, Dien SL, Lau VH, Chahal P, Churchill BM, Haake DA. Uropathogens and host characteristics. <i>J. Clin. Microbiol.<\/i>, <b>46<\/b>, 3980\u20133986 (2008).","key":"14","DOI":"10.1128\/JCM.00339-08"},{"doi-asserted-by":"crossref","unstructured":"15) Ohkawa M, Orito M, Sugata T, Shimamura M, Sawaki M, Nakashita E, Kuroda K, Sasahara K. Pharmacokinetics of cefmetazole in normal subjects and in patients with impaired renal function. <i>Antimicrob. Agents Chemother.<\/i>, <b>18<\/b>, 386\u2013389 (1980).","key":"15","DOI":"10.1128\/AAC.18.3.386"},{"doi-asserted-by":"crossref","unstructured":"16) Tan JS, Salstrom S-J, Signs SA, Hoffman HE, File TM. Pharmacokinetics of intravenous cefmetazole with emphasis on comparison between predicted theoretical levels in tissue and actual skin window fluid levels. <i>Antimicrob. Agents Chemother.<\/i>, <b>33<\/b>, 924\u2013927 (1989).","key":"16","DOI":"10.1128\/AAC.33.6.924"},{"doi-asserted-by":"crossref","unstructured":"17) Craig WA. Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. <i>Clin. Infect. Dis.<\/i>, <b>26<\/b>, 1\u201310 (1998).","key":"17","DOI":"10.1086\/516284"},{"doi-asserted-by":"crossref","unstructured":"18) Takemura W, Tashiro S, Hayashi M, Igarashi Y, Liu X, Mizukami Y, Kojima N, Morita T, Enoki Y, Taguchi K, Yokoyama Y, Nakamura T, Matsumoto K. Cefmetazole as an Alternative to Carbapenems Against Extended-Spectrum Beta-Lactamase-Producing <i>Escherichia coli<\/i> Infections Based on <i>In Vitro<\/i> and <i>In Vivo<\/i> Pharmacokinetics\/Pharmacodynamics Experiments. <i>Pharm. Res.<\/i>, <b>38<\/b>, 1839\u20131846 (2021).","key":"18","DOI":"10.1007\/s11095-021-03140-7"},{"doi-asserted-by":"crossref","unstructured":"19) Ambrose PG, Owens RC Jr, Garvey MJ, Jones RN. Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. <i>J. Antimicrob. Chemother.<\/i>, <b>49<\/b>, 445\u2013453 (2002).","key":"19","DOI":"10.1093\/jac\/49.3.445"},{"doi-asserted-by":"crossref","unstructured":"20) Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. <i>Diagn. Microbiol. Infect. Dis.<\/i>, <b>22<\/b>, 89\u201396 (1995).","key":"20","DOI":"10.1016\/0732-8893(95)00053-D"},{"doi-asserted-by":"crossref","unstructured":"21) Namiki T, Yokoyama Y, Hashi H, Oda R, Jibiki A, Kawazoe H, Matsumoto K, Suzuki S, Nakamura T. Pharmacokinetics\/pharmacodynamics analysis and establishment of optimal dosing regimens using unbound cefmetazole concentration for patients infected with Extended-Spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E). <i>Pharmacotherapy<\/i>, <b>44<\/b>, 149\u2013162 (2024).","key":"21","DOI":"10.1002\/phar.2894"},{"unstructured":"22) Clinical and Laboratory Standards Institute. <i>Performance standards for antimicrobial susceptibility testing: 32nd edition. CLSI supplement M100<\/i>. Clinical and Laboratory Standards Institute, Berwyn, PA, 2022.","key":"22"},{"unstructured":"23) Clinical and Laboratory Standards Institute. <i>Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved tandard 10th edition. CLSI document M07\u2013A10<\/i>. Clinical and Laboratory Standards Institute, Berwyn, PA, 2015.","key":"23"},{"unstructured":"24) Davis J, Goadrich M. \u201cThe Relationship Between Precision-Recall and ROC Curves.\u201d: &lt;https:\/\/ftp.cs.wisc.edu\/machine-learning\/shavlik-group\/davis.icml06.pdf&gt;, accessed 25 November, 2024.","key":"24"},{"unstructured":"25) Movahedi F, Padman R, Antaki JF. \u201cLimitations of ROC on Imbalanced Data: Evaluation of LVAD Mortality Risk Scores. (2020).\u201d: &lt;https:\/\/arxiv.org\/abs\/2010.16253&gt;, accessed 13 January, 2025.","key":"25"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/5\/48_b24-00834\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T03:47:01Z","timestamp":1746848821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/5\/48_b24-00834\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b24-00834","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"type":"print","value":"0918-6158"},{"type":"electronic","value":"1347-5215"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"article-number":"b24-00834"}}